- Repotrectinib
-
-
2026-09-16
- CAS:1802220-02-5
- Min. Order: 1g
- Purity: More Than 99%
- Supply Ability: 50kg/Month
- Repotrectinib
-
- $39.00
-
2026-07-27
- CAS:1802220-02-5
- Purity: 99.85%
- Supply Ability: 10g
|
| Product Name: | Repotrectinib | | Synonyms: | Ropotrectinib;TPX-0005;TPX 0005;TPX0005;CS-2479;Repotrectinib(TPX-005);Repotrectinib;Repotrectinib,TPX-0005;1,15-Etheno-1H-pyrazolo[4,3-f][1,4,8,10]benzoxatriazacyclotridecin-4(5H)-one,11-fluoro-6,7,13,14-tetrahydro-7,13-dimethyl-, (7S,13R)-;TPX-0005,Repotrectinib | | CAS: | 1802220-02-5 | | MF: | C18H18FN5O2 | | MW: | 355.37 | | EINECS: | 125-417-3 | | Product Categories: | API;1802220-02-5 | | Mol File: | 1802220-02-5.mol |  |
| | Repotrectinib Chemical Properties |
| density | 1.46±0.1 g/cm3(Predicted) | | storage temp. | Store at -20°C | | solubility | DMSO:35.0(Max Conc. mg/mL);98.5(Max Conc. mM)
Ethanol:10.0(Max Conc. mg/mL);28.1(Max Conc. mM) | | form | A crystalline solid | | pka | 10.79±0.60(Predicted) | | color | White to off-white | | InChI | InChI=1S/C18H18FN5O2/c1-10-8-20-18(25)14-9-21-24-6-5-16(23-17(14)24)22-11(2)13-7-12(19)3-4-15(13)26-10/h3-7,9-11H,8H2,1-2H3,(H,20,25)(H,22,23)/t10-,11+/m0/s1 | | InChIKey | FIKPXCOQUIZNHB-WDEREUQCSA-N | | SMILES | O1C2=CC=C(F)C=C2[C@@H](C)NC2C=CN3C(N=2)=C(C=N3)C(=O)NC[C@@H]1C |
| | Repotrectinib Usage And Synthesis |
| Binding Mode | The cocrystal structures of repotrectinib with TRK proteins are yet to be reported. However, a docking model with TRKA suggests that the pyrazole nitrogen forms hydrogen bonds with Met592 in the hinge area. The fluorophenyl group, positioned in a hydrophobic pocket, aligns perpendicularly to the macrocycle, and the lactam oxygen atom engages in a water-mediated hydrogen bond with Met592 in the hinge region (Figs. 1,2).
  | | Description | Ropotrectinib (TPX-0005; TP Therapeutics, San Diego, CA, USA) is a nextgeneration ROS1 inhibitor, a novel three-dimensional macrocyle with a much
smaller size (MW <370) than current ROS1 inhibitors. It was specifically
designed to overcome resistance mutations. Preclinical studies have shown activity
against gatekeeper and solvent mutations, including G2032R, D2033N, L2026M,
S1986F/Y, L1951R, and kinases involved in bypass signaling such as focal adhesion
kinase, SRC proto-oncogene, and non-receptor tyrosine kinase [102, 103]. | | Description | Repotrectinib, also known as TPX-0005, is a multikinase (ROS1, ALK, and TRKA/B/C) inhibitor that is tested in an ongoing first-in-human phase 1/2 trail (NCT03093116). | | Brand name | Augtyro | | General Description | Class: receptor tyrosine kinase;
Treatment: NSCLC;
Other name: TPX-0005 | | Biological Activity | Repotrectinib is a potent inhibitor targeting solvent-front mutations (SFMs) of ROS1, pan-TRK, and ALK. It effectively inhibits the kinase activity of wild-type ROS1, TRKA-C, and ALK, along with their SFMs, with IC50 values ranging from 0.071 to 4.46 nM. The compound shows high potency against ROS1 and TRKA-C, with approximately 15-fold selectivity over ALK. | | Clinical Use | Repotrectinib has advantage with central nervous system (CNS) penetration, aimed to target both wide-type (WT) and solvent-front mutations (SFM) kinases and other resistance mutations including ROS1-G2032R and ROS1-D2033N, TRKA-G595R, TRKB-G639R, TRKC-G623R, and ALK-G1202R. | | Side effects | Common side effects of Repotrectinib include dizziness, taste disturbances, and abnormal sensations. Other possible side effects are: constipation, diarrhoea, tiredness, weakness or malaise; swelling of the face, eyes, arms, legs, hands or feet; weight gain; burning, tingling or numbness in the hands and feet. Severe can lead to breathing problems, muscle pain, pressure or weakness; vision changes, bone pain, difficulty moving or skeletal abnormalities. | | target | Primary targets: NTRK, ROS, ALT |
| | Repotrectinib Preparation Products And Raw materials |
|